TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03152370
Drug: E7046
Normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT03152370
Drug: folinic acid/5-FU/oxaliplatin (mFOLFOX-6)
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT02029534
Drug: Atorvastatin 20 mg
Normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02029534
Drug: Atorvastatin 80 mg
Normalized name: atorvastatin 80 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00218517
Drug: Selegiline hydrochloride
Normalized name: Selegiline Hydrochloride
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
Study: NCT00146718
Drug: Amodiaquine and Sulphadoxine/Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01742793
Drug: lenalidomide (Revlimid) and romidepsin (Istodax)
Normalized name: Romidepsin
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02638142
Drug: Continuous Furosemide Infusion
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous continuous Furosemide infusion
Study: NCT02638142
Drug: Intermittent Furosemide Infusion
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous bolus intermittent Furosemide Infusion
Study: NCT04566796
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: give 2 mg/ kg as muscle reversal drug in premature infants
Study: NCT04566796
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants
Study: NCT01010048
Drug: progesterone,tamsulosin,propantheline Bromide and nifedipine
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: clearance rate of stone
Study: NCT02281552
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks
Study: NCT02281552
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
Study: NCT02803918
Drug: Lixisenatide (AVE0010)
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02803918
Drug: Basal Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02803918
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02608112
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.
Study: NCT00677807
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
Study: NCT01924169
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.~If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years.
Study: NCT00113256
Drug: Rubitecan
Normalized name: Rubitecan
DrugBank: Rubitecan (DB06159)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01336686
Drug: Arhalofenate
Normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arhalofenate 400 mg once daily for 4 weeks
Study: NCT01336686
Drug: Arhalofenate
Normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arhalofenate 600 mg once daily for 4 weeks
Study: NCT01336686
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.6 mg colchicine daily for flare prophylaxis
Study: NCT00607763
Drug: Micafungin (Mycamine)
Normalized name: micafungin Injection [Mycamine]
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT03207243
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.
Study: NCT01686646
Drug: paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: paracetamol
Study: NCT00501202
Drug: RWJ-333369 (carisbamate)
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg tablet twice daily for 4 weeks
Study: NCT04019041
Drug: bermekimab
Normalized name: Bermekimab
DrugBank: Bermekimab (DB14947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bermekimab 2 mL (200 mg/mL) pre-filled syringe
Study: NCT04365699
Drug: AT-001
Normalized name: AT-001
DrugBank: AT-001 (DB15121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team
Study: NCT03207243
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.
Study: NCT01618357
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills to be taken twice a day during radiation and for one week after completion of radiation for a total of 29 days.
Study: NCT02165930
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
Study: NCT02165930
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
Study: NCT02165930
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
Study: NCT02165930
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
Study: NCT00189735
Drug: FK778
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01401933
Drug: Linifanib
Normalized name: Linifanib
DrugBank: Linifanib (DB06080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD on Days 1 and 13
Study: NCT01401933
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD on Days 5-16
Study: NCT02540954
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A dose of 2 mg aflibercept injected intravitreally
Study: NCT03947151
Drug: Degarelix injection(s)
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 or 2 degarelix injection(s)
Study: NCT02776228
Drug: Brotizolam
Normalized name: brotizolam
DrugBank: Brotizolam (DB09017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
Study: NCT03925727
Drug: Tavilermide ophthalmic solution
Normalized name: Tavilermide
DrugBank: Tavilermide (DB12441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID topical dosing
Study: NCT01933906
Drug: P1101
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02800330
Drug: Esomeprazole 40mg concomitantly
Normalized name: esomeprazole 40 MG
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
Study: NCT02800330
Drug: Esomeprazole 40mg before
Normalized name: esomeprazole 40 MG
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
Study: NCT02800330
Drug: Regorafenib 160mg or 120mg
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)
Study: NCT00983580
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00983580
Drug: Eflornithine
Normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04023877
Drug: E2027
Normalized name: Elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2027 oral capsule.
Study: NCT02501603
Drug: afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib 40mg daily oral administration
Study: NCT02501603
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80mg/m2 IV weekly (day 1,8,15)
Study: NCT03183596
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-60cc of 0.25% Bupivacaine
Study: NCT03183596
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-4mg of Dexamethasone
Study: NCT02362165
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3mg/㎡,once-weekly,subcutaneous injection
Study: NCT02362165
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40mg/d,once-weekly,per oral
Study: NCT00006211
Drug: Capravirine
Normalized name: Capravirine
DrugBank: Capravirine (DB08502)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006211
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02485028
Drug: Dapoxetine 30mg tablet
Normalized name: duloxetine 30 MG
DrugBank: Dapoxetine (DB04884)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02485028
Drug: Mirodenafil 50mg tablet
Normalized name: Mirodenafil
DrugBank: Mirodenafil (DB11792)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00009919
Drug: semaxanib
Normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00096044
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral
Study: NCT02296112
Drug: trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00218348
Drug: Dextro-Amphetamine Sulfate
Normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03126097
Drug: JNJ-64155806 150 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64155806 150 mg (3\*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 \[JNJ-64155806 Alone Phase\] and on Days 60 to 66 \[JNJ-64155806 + COCP Coadministration Phase\].
Study: NCT01755416
Drug: Closed loop with sensor and Insulin
Normalized name: insulin degludec and liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
Study: NCT01755416
Drug: Closed loop with sensor, Insulin and Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner on Day 1.
Study: NCT01157533
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
Study: NCT00157378
Drug: Risperidone, Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02411331
Drug: Vancomycine 5 mg/ml + Héparine 2500UI/ml
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03087201
Drug: nabiximols
Normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: starting dose (1 puff): 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD, no target dose is defined~Duration of treatment: 13 weeks
Study: NCT00699972
Drug: E2007 (perampanel)
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
Study: NCT00699972
Drug: E2007 (perampanel)
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
Study: NCT02188368
Drug: CFZ
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02188368
Drug: BTZ
Normalized name: BTZ-043
DrugBank: BTZ-043 (DB17737)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02188368
Drug: CLA
Normalized name: CLA
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02710604
Drug: TDF
Normalized name: moxetumomab pasudotox-tdfk
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300mg tablet
Study: NCT00960518
Drug: adefovir
Normalized name: Adefovir
DrugBank: Adefovir (DB13868)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adefovir at 10 mg daily for 48 weeks
Study: NCT00427635
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02487108
Drug: TV-46763
Normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV-46763 will be administered per dose and schedule specified in the arm description.
Study: NCT03638817
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is \< 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count
Study: NCT00827411
Drug: Aspirin and clopidogrel / Prasugrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
Study: NCT00827411
Drug: Aspirin and clopidogrel / Prasugrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
Study: NCT00827411
Drug: Aspirin and clopidogrel / Prasugrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: maintenance dose of clopidogrel / Prasugrel and aspirin
Study: NCT00827411
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interruption of clopidogrel / Prasugrel after one year of follow-up
Study: NCT00107458
Drug: valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02686346
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I:~Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)~Phase II:~BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I
Study: NCT02686346
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m² Days 1-2-3 of Cycles 1-2-3
Study: NCT02686346
Drug: Carboplatine
Normalized name: Carboplatine
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: max 800mg Day 2 of Cycles 1-2-3
Study: NCT01214044
Drug: placebo/escitalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
Study: NCT02686346
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 g/m² Day 2 of Cycles 1-2-3
Study: NCT00749463
Drug: Nicotine Gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
Study: NCT00749463
Drug: Nicotine Patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
Study: NCT01890772
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01890772
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01890772
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03611569
Drug: Lu AF82422
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose
Study: NCT00419562
Drug: Oral Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 mg oral insulin or placebo given before breakfast on a daily basis.
Study: NCT01095588
Drug: 200 mg Avanafil
Normalized name: avanafil 200 MG
DrugBank: Avanafil (DB06237)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 X 100mg tablets avanafil
Study: NCT01933048
Drug: FluMist
Normalized name: FluMist
DrugBank: Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen (DB11037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FluMist Intranasal Vaccine
Study: NCT02244203
Drug: BI 60732
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02250209
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab is given by intravenous infusion at 440mg on day 0every 3 weeks. Number of cycles: 14\~16 cycles.
Study: NCT01403038
Drug: Elagolix
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix Dose Regimen 1 for 84 days
Study: NCT01403038
Drug: Elagolix
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix Dose Regimen 2 for 84 days
Study: NCT01403038
Drug: Elagolix
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix Dose Regimen 3 for 84 days
Study: NCT01403038
Drug: Elagolix
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix Dose Regimen 4 for 84 days Other interventions may be added
Study: NCT01403038
Drug: Elagolix
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix Dose Regimen 5 for 84 days
Study: NCT01403038
Drug: Elagolix
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix Dose Regimen 6 for 84 days